<SEC-DOCUMENT>0001213900-21-040328.txt : 20210804
<SEC-HEADER>0001213900-21-040328.hdr.sgml : 20210804
<ACCEPTANCE-DATETIME>20210804164406
ACCESSION NUMBER:		0001213900-21-040328
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210804
FILED AS OF DATE:		20210804
DATE AS OF CHANGE:		20210804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd./ADR
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		211144687

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea145232-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">For the month of August 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0pt; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&nbsp;</B>Note: Regulation S-T Rule 101(b)(
1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Note</B>: Regulation S-T Rule 101(b)(7)
only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0pt; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0pt; text-align: justify; text-indent: 0.5in">On August 4,
2021, SciSparc Ltd. (the &ldquo;<B>Company</B>&rdquo;) issued a press release titled: &ldquo;SciSparc Announces Completion of Corporate
Rebranding and Launch of New Website&rdquo;. A copy of this press release is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ea145232ex99-1_scisparc.htm">Press release titled: &ldquo;SciSparc Announces Completion of Corporate Rebranding and Launch of New Website&rdquo;.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; background-color: white"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B><U>SciSparc Ltd.</U></B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: August 4, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 65%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 25%"><FONT STYLE="font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 11.95pt 0.05in 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea145232ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE TITLED: SCISPARC ANNOUNCES COMPLETION OF CORPORATE REBRANDING AND LAUNCH OF NEW WEBSITE.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><BR>Exhibit 99.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SciSparc Announces Completion of Corporate Rebranding and Launch of New Website</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">TEL AVIV, Israel, Aug. 4, 2021 /PRNewswire/
--&nbsp;SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based
treatments, today announced it has completed the rebranding process including, among others, a new name, brand logo,a new website and&nbsp;<FONT STYLE="color: blue">investor
lobby</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="SciSparc Ltd Logo" STYLE="height: 400px; width: 400px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SciSparc's corporate rebrand reflects the Company's
business direction and plans to develop proprietary compounds that capitalize on the biochemistry of receptors that specialize in modulating
the central nervous system (CNS) to create therapeutics that mitigate the adverse symptoms associated with CNS disorders. SciSparc has
four drug candidates in clinical trials with applications for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's Disease (AD) and
Agitation, and Autism Spectrum Disorder, and two in pre-clinical studies for Status Epilepticus, and Chronic Pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&nbsp;<FONT STYLE="color: blue">recently
provided an update</FONT>&nbsp;on its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment,
SCI-110. SciSparc intends to evaluate the efficacy, safety and tolerability of its SCI-110 in a randomized, double-blind, placebo controlled,
cross-over study. In addition,&nbsp;<FONT STYLE="color: blue">SciSparc received approval</FONT>&nbsp;from the Israeli Ministry of Health
and Helsinki Committee to commence a Phase IIa Clinical Trial of SCI-110 in patients with AD and Agitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&quot;We are excited about the progress SciSparc
has made in both Tourette Syndrome and Alzheimer's Disease and Agitation,&quot; said Amitay Weiss, SciSparc's Chief Executive Officer.
&quot;We believe this rebranding and new website reflect SciSparc's vision and dedication to the development of cannabinoid-based treatments.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About SciSparc (OTCQB:&nbsp;SPRCY):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio
of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for the treatment of Tourette
syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment of pain; and SCI-210 (formerly
THX-210) for the treatment of autism spectrum disorder and epilepsy.&nbsp;&nbsp;<FONT STYLE="color: blue">https://scisparc.com/</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: blue">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This press release contains forward-looking
statements within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses&nbsp;the expected clinical trials
and studies and the potential efficacy, safety and tolerability of SCI-110. Historic results of scientific research and clinical and preclinical
trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because
such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements
in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties,
including those discussed under the heading &quot;Risk Factors&quot; in SciSparc's Annual Report on Form 20-F filed with the SEC on March
30, 2021, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims
any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Investor Contact:<BR>
</B><FONT STYLE="color: blue">IR@scisparc.com</FONT><BR>
Tel: +972-3-6167055&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0$<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     0 < 5H  QLE1QP">  24V-I4W!A<F,@3'1D+B!,;V=O' ):  A414P@
M059)5AP"=  ! !P"90 ! !P"4  (2&%N9"UO=70< E\  0 < AD  0 < FD
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M%A<7%PX1&1L9%AH4%A<6_\  "P@!D &0 0$1 /_$ !T  0 #  ,! 0$
M       '" D$!08# 0+_Q !3$  ! P,"! ,% P8("0H'     0(#! 4&!Q$(
M$B$Q$T%1"10B87$R0H$5(U)BD9(7&20S5G*"H18T-T-CHK'2TQ@E4U=U@Y.5
MM,,V<W1VLL3C_]H " $!   _ +_
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MOFOMYR6FK\'EM=#:YEDH[C [F@\-SMF02JO>;;KNWHJ;]$Z;V2
M      !&W$/KOIMHM9V5>;WQ(JJH:KJ6VTS?%JZGYMC3LW]9RHGS*O7/VE>-
M,N2LM^EMUFI$=MXL]TCCD5/7D1CD3]XF?ARXQ](=6KG#8XZRHQR^U"HV&WW?
ME8D[OT8Y456.7Y+LJ^2%@R$>.[7N#0;21+K2015>0WB1U+9J:7JQ'HF[I7IY
ML8BIT\U5J>96;AAX6<CX@&0ZR\0647:M@O'Y^WVULRMEJ(57HYSNT42_=8Q$
M7;KNA<[3C1K2S J2.#$\"L5N6-$1)FT;7S+\UE<BO5?JIG-Q>UT.@OM(Y,OQ
M7:-D%937B:FCZ)^>8BSQ;)Y/17]/US43%[Q09!C=!?;5.V>AN=+'54TK5Z/C
M>U'-7]BH9D:WI_ Q[5J"_-3P:*IR"EN2JG1%@JT1LWX;OE_8:BIU3= 1MQ(:
M&:?:W8RVUYG;%=44Z+[E<J94954BK^@_9=V^K5147T*;9'[.O4"T7B27 M4;
M>M,Y?@=5LFI)T;Z.6+F1?[OH=KIS[.:XU-\CN&I^I#:N!'(Z6FM43W2S)Z+-
M+]G]U2[NF.$8MIYAM)BV'V>GM=KHV[1PPIU<OF][EZN<OFY>JGH
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MRS"K9>;Q2T[:>&HK8UD1C&N5S4Y%7E797+U5-SW+41K4:U$1$39$3R/T
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M+<!H\/PVV-H;=2)NO7FDGD7[4DCN[GKYK^'1$1#U0
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M\5G]SF^CNNI&%9#9\MQ.WY+C];'6VRZ4[:BEJ(UW1[')NGT7R5/)45#M
M                ",^*;1'$]=-.G8SDC7T]13N6:VW*%J+-12[;<R;]VKV<
MU>Z>BHBI0"^<"W$=CEYJ+;B]907"VSNV]ZH[Q[JR5ODLD;E:J+MY?%]5)8X<
M/9X4]%<(+UK)?H:_PW(]+):GN2)Z^DLZHBJGJC43^L7DQ>QV?&[#362P6REM
MMNHHTCIZ6EB2..)J>2-0YYF9J9/3:G>UWMS,3Y9HJ"_43)YX>K7>YL:Z=^Z>
M2>&YN_R-,R'N-'0:T:]:7?D*::&@O=!)X]HN;X^;W=_1'-=MU5CDZ*GJB+Y'
M=\+6DEOT4TCH\'MUYK[LR&1T\M15OZ+(_97)&SM&S=-T:F_=5W554D8
M              $/XMK+D-SXK[UI'5Z;WBDME!0I54F02)RPS-1$YGJB]%8Y
MRHUJM55W1=T3RF  X=]N]JLEMDN%YN5);Z2).:2HJYVQ1L3U5SE1$*2\;?&Y
M:V6JIP#1"K?=+M7[TU1?:=JK'3H[HK:;SDD7?9')T3RW7MZ[V8W#77:862?4
M?.J9S,MOL')3TLO5]NIG*CE1_P#I7KLKO1$1.ZJ6X
M  /S9.;?;KZE?N*2Z\1."9_!J'IU3T66X;34;8KIB;8>6J;LJJ^>-R;N<[K]
MWLB;<KNYZ_ALX@-/=:;0K\;N"TEXIV_R^QUVT=92.3HN[?O-1?O-W3UV7H2F
MO8SBR3@@U\S[4>ZU&39G1TUE?<IWT<UQNDU;+X"R.5BMC3=$7EVZ*Y"S/"QP
M?Z9:-54-\<R3),EB3=MTN$:<M.[UAB3=&+^LJJ[YEA
M    >8U2U$PC3BP_EG.,EH++1KNC'54NSI53R8Q-W/7Y-13M<-O]IRK%+=DE
MAJVU=LNM,RJI)VHJ))&]-VKLO5.B]EZH0OQ)\+N+:B7=,SQ&NFPG/:5WBTM^
MM>\?BR)V\=K=N;^LFSOJG0\-@/$CG&DN44VGO%)9%MTDCO"MV9T4:NH*]$Z(
MLG*FR+ZJB(J?>:G<M59[C07:UP7*UUM/6T=5&DD%13R))'*U>RM<G14.2
M                  #SNK686S3_ $TOF:7A5]RLE#)52M1>K^5/A8GS<[9J
M?-2L'#!H<NMTL>O^O\;K[7WY5J+#8)W+[E;:/?\ -[Q_>W3JC5Z;;*J*J]+<
MVJAHK9;H;?;:."CI*9B,AIZ>-(XXFIV1K4Z(GR0X>:9#:,3Q.X9+?JKW6V6J
MG=4U<_(Y_AQM3=7;-157\$.CDIL"UHTEI9ZR@H\AQC(:1E1"RIAW;(QR;HY$
M7JQR>J;*BG8Z7X7CNGN"6_#\4H4HK3;(UCIX>=7*FZJY55R]5555555]3OP
M                    0)[3>DKJS@HS)M"CE=$RFFF1O_1-J8U?^"(F_P"!
M)^@UPMEUT2Q&XV9S'4%18J1U/R=D;X+4V_#;;\#UAY37:2W1:)Y>^[N8VA2P
MUOO"O[<G@/W(P]F3[_\ \BC#/R@CD7PZGP>;OX7O,O)^&Q/0
M         !U^566VY'C-PL%XIFU-ON=+)2U4+NSXWM5KD_8I3+ \XS+@PO\
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M4>EVM5-%26FY?DG(%;O)9+B]&3JOGX3OLRI_5Z^J(38
M     "'^)CAJTOULH7RY%:4H;VC.6"]T")'5,].==MI&_)R+\E0SFXG^#W5/
M2%U1=(*-<FQN-5<ETML2N="WUFAZN9]4W;\RO1]*2HGI:J.II9Y()H7(^.6-
MZM<QR=E14ZHI<KA'X\LGQ%U+C6K:5&161NT<=V9UKJ1O;=__ $S4^?Q?->QH
MGIUF6+YYBE-DF(7JDNULJV[QU%,_F1%\VN3NUR>;51%0[T
M        _'(CFJUR(J*FRHOF5EXI^"G3;5)*F]8U%'B.2R;O]YHXD]UJ7_Z6
M%-DW7])FR^NYG%Q":':C:,7_ /)V:V.2&GD<J4MRI]Y*2J3]21$VW_579R>A
M')(O#EK9GNBN7MO>'71S89')[[;9U5U+6L3[KV>OHY-E3R4U<X2^(7"M>,1]
M]LDR4-[I&)^4[-.]%FIE_2;^G&J]G)]%V4ET                      '6
M9ACMBRO':FPY+::2ZVVL9R3TM7$DD;T^B^?HJ=4,\>-'@3N.,Q5>8Z.,J+I:
M6(LM587JKZJE;W585[RM3]%?B3]8I)*Q\<CHY&.8]BJUS7)LK53NBH=]IAFN
M2Z>YO0Y;B5TEMUTM\G/%+&O1R>;'IV<U4Z*U>BH:^\&.O=BUYTP9>:9(Z.^V
M_EAO5L1VZP2[='L\UC?LJM7ZHO5"80                      "F7M%.$"
MFSFCJM1]+[7'#E$2+)<K9 B,9=6^;V)V29/]?Z]\TJRGJ*2KEI:J"2">!ZQR
MQ2-5KHW(NRM5%ZHJ+Y$F\'VKURT7UPM664TLBVU\B4UXIFKTJ*5ZISIMZM^T
MWYM0VFME937&VT]PHIFS4U7"V:&5B[H]CD16N3Y*BHI]P
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M:>E2H>Z25?DC-]OGLGF;&8Y:J*QX_0V6VPI#1VZFCIJ>-.S(V-1K4_8B'-
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MBJN[>9$7;KYH>W
M             *P^U"UT?I5HVF-8]<'4^4Y4CH::2%_++1TR?SLR*G5JK]AJ
M^JJJ?9/5>SPK]4;QPV6N^:IW>2X5MR<LUL6>)&U#:/9$C65R?;<[97(J]>54
MW52=                       #I]0,HLN%X5<\JR*L926RTTSJBIF<O9K4
M[)ZJJ[(B>:JB&96D5CR#C0XU*O*<CAECQ>WRMJ*R-5^"FHF._,TC5_2?MU^K
MW&I-)!!2TD5+31,BA@8D<4;&[-8U$V1$3R1$0^@
M !1?VM]=JWDE^QC3#&L7N3L:NU1'M64Z<[+G6N=LR%RM^PC.^SMMU7?LTLEP
M<Z+VO0_1BAQ:F2.:ZS[5-YK6IUJ:E4Z[+^@U/A;\DW[JI*P
M          /Q[6NVYFHO*NZ;IV7U/T
M                 $*\9W$7C&@V$+/4.BN&35\:I:;0C_BD7MXLFW5L2+W7
MNO9/E!7LO+SQ 9YGN1:D9=>YI<-O+WNECKF*K:FJ3HWW1N_YMC$1&JJ?"J(B
M;*O5+O@                      %=^-WBJQ?0ZRRV:UN@O&:5,7\FMS7[L
MHT5.DM0J=D\T9W=\DZE4^$SAVSGB7U"DU?UFK:Y<>J9_&5\ZJR:[JB](XD_S
M<"=MTV3;HWS5-*;!:K;8[+2V>ST,%#04,+8::F@8C(XF-39&M1.R'+
M                 *M7;@@T_O/$[<-3+W75%=9*V1*U<?E57-?5JJJ]7R*N
MZQ;[*C/553?9-BT%%34]'1Q4E)!'!! Q(XHHF(UD;439&HB=$1$\CZ@
M                'P=6T3;DVWK5P)6/B65M.LB>(YB*B*Y&]^5%5$W[=3[@
M                      '39UEF,X7C\U\RN^T%GMT";OJ:R=L;?HF_=?DF
MZE).)7V@C7S2XUH=9Y*NIE=X3;Y70*J*Y>B>!3]W+Z*_]U3C\#>@_$'=]<+?
MKKJ/DMPLKT57/BN2K+6W.%R;.B=$JHD4:IY+LJ;)LWHBE_
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M^_KSR\RHOTV)3C8R.-K(VM:UJ;-:U-D1/D?T
*         #__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
